Navigation Links
Chimerix Updates the World Health Organization and the Global Health Security Initiative on Development of CMX001 as a Broad-Spectrum Therapeutic for Smallpox
Date:11/6/2009

treatment of cytomegalovirus (CMV) and BK virus in immunocompromised transplant patients. The company has also received a grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) to support the development of CMX001 as a treatment in the event of a smallpox outbreak.

About the GHSI Meeting

This year's GHSI workshop was hosted by the United States Department of Health and Human Services, Assistant Secretary for Preparedness and Response (ASPR), and the Biomedical Advanced Research and Development Authority (BARDA) in Washington, DC. The GHSI consists of the Group of Seven nations, along with Mexico, and is charged with facilitating international cooperation for the development and procurement of medical countermeasures for both biodefense and global health. More information about the meeting may be found at http://www.blsmeetings.net/2009GHSImeetingsMCM/index.html

About Chimerix

Chimerix, Inc., is developing antiviral therapeutics to treat life-threatening diseases. Led by a world-class antiviral drug development team, Chimerix is advancing programs to address cytomegalovirus (CMV), BK virus, smallpox, human immunodeficiency virus (HIV), hepatitis C virus (HCV), respiratory syncytial virus (RSV) and influenza. The company's lead compound, CMX001, is currently in Phase 1 and 2 clinical studies for the treatment of BK virus and CMV, potentially deadly infections among immunocompromised patients. CMX001 is also being evaluated for use as a treatment in the event of a smallpox outbreak. Chimerix has received financing from leading venture capital firms, including Canaan Partners, Alta Partners, Sanderling Ventures, Frazier Healthcare Ventures and Asset Management Company, in addition to U.S. Government grants. Additional information about Chimerix and its antiviral drug dev
'/>"/>

SOURCE Chimerix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Chimerix Initiates a Multi-dose Clinical Trial of the Companys Lead Compound, CMX001, for the Treatment for Smallpox Infection
2. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
3. Diamyd Updates Gene Therapy Program and Outlines Plans for Phase I Clinical Trial for Treatment of Cancer Pain
4. Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program
5. Wyeth Presents New Phase 3 Data and Updates Regulatory Timing for NDA Filing of Bazedoxifene/Conjugated Estrogens
6. Alliance Pharmaceutical Corp. Updates Oxygent(TM) Clinical Development Plan
7. Imaging Diagnostic Systems Updates PMA Filing Status for the New CT Laser Breast Imaging System
8. BioCryst Updates Peramivir Clinical Development Plan
9. Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program
10. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
11. Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)...   , July 2, 2015 BGI ... Hong Kong has been accredited ... Kong facility is the first clinical next-generation-sequencing laboratory to ... , meeting the highest standard in clinical laboratory practices. Complementary ... 11 compliant laboratory process, and multiple ISO certifications, the ...
(Date:7/1/2015)... The Coalition of State Rheumatology Organizations ... professional rheumatology societies, today released the findings of ... of biosimilars and the potential impact of these ... are medicines that are highly similar, but not ... from generic medications in that it is impossible ...
(Date:7/1/2015)... -- Eli Lilly and Company (NYSE: LLY ) will ... on Thursday, July 23, 2015. Lilly will also conduct a ... media to further detail the company,s financial performance. ... media and the general public can access a live webcast ... posted on Lilly,s website at www.lilly.com . A replay ...
Breaking Medicine Technology:BGI Receives Accreditation from the College of American Pathologists (CAP) 2Survey Of Rheumatologists Nationwide Regarding Biosimilars Highlights Need For More Robust FDA Standards 2Lilly Confirms Date and Conference Call for Second-Quarter 2015 Financial Results Announcement 2
... Mylan Inc. (Nasdaq: MYL ) today ... entered into a settlement agreement with Warner Chilcott resolving ... as Norethindrone and Ethinyl Estradiol Tablets USP (Chewable), 0.4 ... mg (28-Day Regimen). This medication is an oral contraceptive. ...
... NEW YORK, Oct. 19, 2011 Reportlinker.com announces ... in its catalogue: Syncria ... 2020 http://www.reportlinker.com/p0657174/Syncria-Type-2-Diabetes-–-Analysis-and-Forecasts-to-2020.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology ... and Forecasts to 2020 Summary ...
Cached Medicine Technology:Mylan Announces Femcon® Fe Settlement Agreement 2Syncria (Type 2 Diabetes) - Analysis and Forecasts to 2020 2Syncria (Type 2 Diabetes) - Analysis and Forecasts to 2020 3Syncria (Type 2 Diabetes) - Analysis and Forecasts to 2020 4Syncria (Type 2 Diabetes) - Analysis and Forecasts to 2020 5
(Date:7/2/2015)... , ... July 02, 2015 , ... After conducting a ... Yuma Regional Medical Center in Yuma, Ariz., has hired Robert Trenschel, DO, ... healthcare and medical management, Dr. Trenschel will assume his new duties at Yuma Regional ...
(Date:7/2/2015)... ... July 02, 2015 , ... The report ... Capsule manufacturers. The report is a valuable source of guidance and direction for ... and Chinese market for the Gelatin Capsule industry including capacity, production, production value, ...
(Date:7/2/2015)... ... July 02, 2015 , ... ... is announcing with their launch an intention to partner with companies that share ... on the planet. Their innovative water soluble, Cannabidiol (CBD) formulations, combined with Ayurvedic ...
(Date:7/2/2015)... AL (PRWEB) , ... July 02, 2015 , ... Every year, DUI arrests and fatalities ... July may be the deadliest day of the year when it comes to being on ... “The National Highway Traffic Safety Association reports that 40% of all highway deaths between 2007 ...
(Date:7/2/2015)... ... 2015 , ... Today, East Liverpool City Hospital announced Pam Akin, RN, MSN, ... Hospital (ELCH). Pam is currently the Chief Nursing Officer at ELCH and will remain ... a master’s degree in health care administration as well as nursing. She has a ...
Breaking Medicine News(10 mins):Health News:Yuma Regional Medical Center Hires New Chief Executive Officer 2Health News:Yuma Regional Medical Center Hires New Chief Executive Officer 3Health News:Gelatin Capsule Market Outlook & Forecast Report 2015-2020 2Health News:Gelatin Capsule Market Outlook & Forecast Report 2015-2020 3Health News:Gelatin Capsule Market Outlook & Forecast Report 2015-2020 4Health News:New Water Soluble CBD Provides Manufacturers & Distributors a More Effective, Safe, & Cost Efficient Alternative to Traditional CBD Oil 2Health News:New Water Soluble CBD Provides Manufacturers & Distributors a More Effective, Safe, & Cost Efficient Alternative to Traditional CBD Oil 3Health News:Attorney David Maloney Stresses Safety through Sobriety 2Health News:East Liverpool City Hospital Announces New Surgical Center Leadership 2Health News:East Liverpool City Hospital Announces New Surgical Center Leadership 3
... Francisco Bay Area Affiliate of Susan G. Komen for the ... to applaud the introduction of the 21st Century Cancer ALERT ... Detection, R esearch and T reatment) Act, bipartisan ... and Kay Bailey Hutchison (R-TX). "It,s been more than ...
... from fertility clinic embryos that otherwise would be discarded ... to use U.S. funding for embryonic stem cell research ... would be discarded, the National Institutes of Health announced ... research -- such as using stem cells taken from ...
... April 17 Even though suicide outranks homicide as ... death certificates thwart healthcare policymakers who want to create ... a WVU study shows."The Institute of Medicine ... have been diagnosed with a mental disorder, but death ...
... United States Great Depression of 1929 has the American ... well-being across the parameters of occupational, spiritual, emotional, and ... people are at risk for suffering lowered self esteem, ... St. Thomas University Counseling Programs - initiated ...
... Penny Imaging Exchange has acquired new German technology to process the ... ... Bohemia, NY (Vocus) April 17, 2009 -- Penny Imaging ... the conversion of microfiche records to digital form - the ...
... (Nasdaq: SUAI ) ("SUA" or the ... leading independent proxy advisory firm, has recommended that stockholders vote ... nominees recommended by dissident stockholder Hallmark Financial Services, Inc. ("Hallmark"). ... 9:00 a.m. local time on May 5, 2009 at 222 ...
Cached Medicine News:Health News:San Francisco Bay Area Affiliate of Susan G. Komen for the Cure(R) Applauds Introduction of Bipartisan Cancer Alert Act 2Health News:San Francisco Bay Area Affiliate of Susan G. Komen for the Cure(R) Applauds Introduction of Bipartisan Cancer Alert Act 3Health News:NIH May Ease Some, But Not All, Stem Cell Restrictions 2Health News:NIH May Ease Some, But Not All, Stem Cell Restrictions 3Health News:NIH May Ease Some, But Not All, Stem Cell Restrictions 4Health News:Team Uncovers Discrepancy in Death Certificates Listing Suicide 2Health News:Good News for Tough Times: Small, Private University Responds to Today's Economic Challenges 2Health News:Penny Imaging Exchange, Inc. Acquires New Technology to Capture Medical Records from Microfiche 2Health News:Penny Imaging Exchange, Inc. Acquires New Technology to Capture Medical Records from Microfiche 3Health News:Leading Independent Proxy Advisory Firm Supports Specialty Underwriters' Alliance, Inc. in Its Proxy Contest Against Hallmark Financial Services, Inc. 2Health News:Leading Independent Proxy Advisory Firm Supports Specialty Underwriters' Alliance, Inc. in Its Proxy Contest Against Hallmark Financial Services, Inc. 3
... Digital Flexible Ureteroscope (DUR-D) incorporates many ... proven durable, market leading DUR® series ... first device utilizing Gyrus ACMIs proprietary, ... Metal Oxide Semi-Conductor (CMOS) distal sensor ...
... is the first one-step 20 minutes rapid test ... 2 produced by Enterohemorrhagic Escherichia coli in human ... enrichment of fecal specimens and detects all Toxigenic ... separate result for Toxin 1 and 2 is ...
Inquire...
... elegant and sophisticated woman, the ... ophthalmic and sunwear styles. Frames ... of shapes and colors, designed ... and complexions. Many styles feature ...
Medicine Products: